DE3704868C2 - Reinigung von rekombinantem Human-Interleukin-1 - Google Patents
Reinigung von rekombinantem Human-Interleukin-1Info
- Publication number
- DE3704868C2 DE3704868C2 DE3704868A DE3704868A DE3704868C2 DE 3704868 C2 DE3704868 C2 DE 3704868C2 DE 3704868 A DE3704868 A DE 3704868A DE 3704868 A DE3704868 A DE 3704868A DE 3704868 C2 DE3704868 C2 DE 3704868C2
- Authority
- DE
- Germany
- Prior art keywords
- human interleukin
- buffered
- tris
- solution
- column
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010002352 Interleukin-1 Proteins 0.000 title claims description 24
- 102000000589 Interleukin-1 Human genes 0.000 title claims description 24
- 238000000746 purification Methods 0.000 title description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 18
- 239000007983 Tris buffer Substances 0.000 claims description 13
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 13
- 239000012506 Sephacryl® Substances 0.000 claims description 10
- 210000000172 cytosol Anatomy 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 239000002158 endotoxin Substances 0.000 claims description 7
- 239000007975 buffered saline Substances 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 238000002523 gelfiltration Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 239000008366 buffered solution Substances 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 2
- 150000002500 ions Chemical group 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 108010025899 gelatin film Proteins 0.000 claims 1
- 238000004255 ion exchange chromatography Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000009210 therapy by ultrasound Methods 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 18
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000003000 inclusion body Anatomy 0.000 description 5
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 229960002385 streptomycin sulfate Drugs 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102100033468 Lysozyme C Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108010065081 Phosphorylase b Proteins 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011013 endotoxin removal Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 229940124272 protein stabilizer Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/141—Interleukin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/830,406 US5831022A (en) | 1986-02-18 | 1986-02-18 | Purification of recombinant human IL-1α |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3704868A1 DE3704868A1 (de) | 1987-08-20 |
| DE3704868C2 true DE3704868C2 (de) | 1995-09-21 |
Family
ID=25256938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3704868A Expired - Fee Related DE3704868C2 (de) | 1986-02-18 | 1987-02-16 | Reinigung von rekombinantem Human-Interleukin-1 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5831022A (enExample) |
| JP (1) | JP2590085B2 (enExample) |
| BE (1) | BE1000636A5 (enExample) |
| CH (1) | CH676008A5 (enExample) |
| DE (1) | DE3704868C2 (enExample) |
| DK (1) | DK171419B1 (enExample) |
| FR (1) | FR2595714B1 (enExample) |
| GB (1) | GB2186580B (enExample) |
| IT (1) | IT1202565B (enExample) |
| NL (1) | NL8700397A (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE92766T1 (de) * | 1987-12-18 | 1993-08-15 | Immunex Corp | Oertliche wundheilmittel, die interleukin-1proteine enthalten. |
| US5120534A (en) * | 1988-07-29 | 1992-06-09 | Otsuka Pharmaceutical Co., Ltd. | IL-1α derivatives and medicament for treating thrombocytopenia |
| IT1226713B (it) * | 1988-08-05 | 1991-02-05 | Eniricerche Spa | Procedimento per la preparazione di interleuchina 1 beta umana ricombinante in forma omogenea. |
| CZ296806B6 (cs) * | 1994-10-24 | 2006-06-14 | Allergan, Inc. | Rozpustný fúzní protein a zpusob výroby rozpustného rekombinantního botulinového toxinu |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4401756A (en) * | 1981-04-14 | 1983-08-30 | Immunex Corporation | Process for preparing human interleukin 2 |
| CA1341562C (en) * | 1982-03-31 | 2007-11-27 | Tadatsugu Taniguchi | Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell |
| GR79124B (enExample) * | 1982-12-22 | 1984-10-02 | Genentech Inc | |
| FR2550802B1 (fr) * | 1983-08-17 | 1986-04-11 | Inst Nat Sante Rech Med | Procede de production d'interleukine 1 humaine et medicaments correspondants |
| DK174501B1 (da) * | 1983-12-23 | 2003-04-28 | Hoffmann La Roche | Fremgangsmåde til fremstilling af interleukin-2 |
| JPS60149386A (ja) * | 1984-01-17 | 1985-08-06 | Dainippon Pharmaceut Co Ltd | インタ−ロイキン１をコ−ドする伝令リボ核酸及びその調製法 |
| JPS60197629A (ja) * | 1984-03-16 | 1985-10-07 | Chemo Sero Therapeut Res Inst | ＨＢｓ抗原の精製方法 |
| DE3419995A1 (de) * | 1984-05-29 | 1985-12-05 | Hoechst Ag, 6230 Frankfurt | Gentechnologisches verfahren zur herstellung von human-interleukin-2 und mittel zur durchfuehrung dieses verfahrens |
| JPS617296A (ja) * | 1984-06-19 | 1986-01-13 | イミユネツクス、コ−ポレ−シヨン | インタ−ロイキン１の遺伝子の精製、クロ−ニング及び特性づけ |
| CA1341433C (en) * | 1984-06-19 | 2003-06-24 | Douglas P. Cerretti | Purification of interleukin 1 |
| DE3432196A1 (de) * | 1984-09-01 | 1986-03-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Neues mechanisches aufschlussverfahren von bakterienzellen zur isolierung von rekombinant hergestellten peptiden |
| DE3683186D1 (de) * | 1985-04-25 | 1992-02-13 | Hoffmann La Roche | Rekombinantes humaninterleukin-1. |
| US4675387A (en) * | 1985-07-26 | 1987-06-23 | E. I. Du Pont De Nemours And Company | Method for extracting protein with organic acid |
| US5008374A (en) * | 1986-03-14 | 1991-04-16 | Otsuka Pharmaceutical Co., Ltd. | IL-1α derivatives and drugs |
| US4801686A (en) * | 1986-09-04 | 1989-01-31 | Immunex Corporation | Purification of recombinant interleukin-1 |
-
1986
- 1986-02-18 US US06/830,406 patent/US5831022A/en not_active Expired - Lifetime
-
1987
- 1987-01-13 CH CH98/87A patent/CH676008A5/de not_active IP Right Cessation
- 1987-02-12 FR FR878702010A patent/FR2595714B1/fr not_active Expired - Lifetime
- 1987-02-16 DK DK077387A patent/DK171419B1/da not_active IP Right Cessation
- 1987-02-16 DE DE3704868A patent/DE3704868C2/de not_active Expired - Fee Related
- 1987-02-17 GB GB8703663A patent/GB2186580B/en not_active Expired - Lifetime
- 1987-02-17 JP JP62034385A patent/JP2590085B2/ja not_active Expired - Lifetime
- 1987-02-17 NL NL8700397A patent/NL8700397A/nl not_active Application Discontinuation
- 1987-02-18 BE BE8700134A patent/BE1000636A5/fr not_active IP Right Cessation
- 1987-02-18 IT IT19420/87A patent/IT1202565B/it active
Also Published As
| Publication number | Publication date |
|---|---|
| FR2595714A1 (fr) | 1987-09-18 |
| GB2186580A (en) | 1987-08-19 |
| DK77387A (da) | 1987-08-19 |
| US5831022A (en) | 1998-11-03 |
| CH676008A5 (enExample) | 1990-11-30 |
| NL8700397A (nl) | 1987-09-16 |
| DK77387D0 (da) | 1987-02-16 |
| GB2186580B (en) | 1990-08-22 |
| FR2595714B1 (fr) | 1990-05-18 |
| BE1000636A5 (fr) | 1989-02-28 |
| GB8703663D0 (en) | 1987-03-25 |
| JP2590085B2 (ja) | 1997-03-12 |
| IT1202565B (it) | 1989-02-09 |
| IT8719420A0 (it) | 1987-02-18 |
| DE3704868A1 (de) | 1987-08-20 |
| DK171419B1 (da) | 1996-10-21 |
| JPS62209097A (ja) | 1987-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69224858T2 (de) | Essentiell reines menschliches Parathyroidhormon | |
| DE60115383T2 (de) | Hochreine lipopeptide, lipopeptid mizellen, deren herstellung und arzneimittel | |
| DE3586762T2 (de) | Gereinigtes rekombinantes interleukin-2 und verfahren zu dessen rueckgewinnung und reinigung. | |
| DE69028671T2 (de) | Löslisches extrazellulares Fragment des menschlischen IFN-beta 2/IL-6-Rezeptors, seine Herstellung und diesen Fragment enthaltende pharmazeutische Mischung | |
| DE3877529T2 (de) | Herstellung von hoch-gereingtem menschlichen Faktor IX sowie anderem Plasmaproteinkonzentrat und dessen therapeutische Verwendung. | |
| DE3177288T3 (de) | Reife menschliche Leukozyten-Interferone, Verfahren zu ihrer bacteriellen Herstellung, Zwischenprodukte hierfür und Zusammensetzungen diese enthaltend. | |
| DE3686470T2 (de) | Verfahren zur herstellung des alpha-1-proteinase-inhibitors. | |
| DE3686475T2 (de) | Verfahren zur herstellung des alpha-1-proteinase-inhibitors. | |
| DE3650276T2 (de) | Proteinreinigung. | |
| DE69103755T2 (de) | Wachstumshormonkristalle und verfahren zu deren herstellung. | |
| CH664967A5 (de) | Im wesentlichen reine mrna's des menschlichen fibroblasten-interferons. | |
| DE69125764T2 (de) | Verfahren zur Herstellung des Von Willebrand-Faktors von höchster Reinheit | |
| DE3877547T2 (de) | Basisches protein phospholipase a2 aus dem gift der schlangen aus der familie der elapiden, deren aminosaeuresequenz, derivate und fragmente dieses proteins, verfahren um es zu erhalten, therapeutische kompositionen und diagnosemittel, alle dieses protein enthaltend und/oder dessen derivate und/oder dessen fragmente. | |
| DE3402647C2 (de) | Verfahren zur Gewinnung von koloniestimulierendem Faktor und Kallikrein aus menschlichem Urin | |
| DE3039566A1 (de) | Verfahren zur reinigung von interferon | |
| DD296842A5 (de) | Verfahren zur herstellung von gereinigten albuminloesungen | |
| EP0271885A2 (de) | Arzneimittel enthaltend das Gewebeprotein PP4, Verfahren zur Herstellung von PP4 und zu seiner Pasteurisierung sowie die Verwendung von PP4 | |
| DE3704868C2 (de) | Reinigung von rekombinantem Human-Interleukin-1 | |
| DE3515336C2 (de) | Verfahren zur Herstellung und Reinigung von â-Interferon | |
| EP0250000B1 (de) | Neue Polypeptide, ihre Herstellung und ihre Verwendung | |
| DE1940130C2 (de) | Verfahren zur Reinigung von Insulin, nach diesem Verfahren gereinigtes Insulin und dessen Verwendung | |
| EP1478662B1 (de) | Verfahren zur herstellung von hypoallergenem birkenpollenhauptallergen rbet v 1 | |
| DE3110611A1 (de) | "mitogene der leukozyten und des entzuendungsgewebes:natuerliche leukopoetine zur selektiven anregung der teilung und differenzierung von leukozyten" | |
| DE3687246T2 (de) | Antitumor-polypeptid und dessen methode zur herstellung. | |
| EP0083734B1 (de) | Kristallines Human-Leukocyten-Interferon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8101 | Request for examination as to novelty | ||
| 8105 | Search report available | ||
| 8127 | New person/name/address of the applicant |
Owner name: F. HOFFMANN-LA ROCHE AG, BASEL, CH |
|
| 8128 | New person/name/address of the agent |
Representative=s name: LEDERER, F., DIPL.-CHEM. DR., 8000 MUENCHEN RIEDER |
|
| 8110 | Request for examination paragraph 44 | ||
| 8125 | Change of the main classification |
Ipc: C12P 21/00 |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |